#### **CERTIFICATE OF CORRECTION**

PATENT NO. : 7,071,205 B2 Page 1 of 10

APPLICATION NO.: 10/684229
DATED: July 4, 2006
INVENTOR(S): Lin Zhi et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

#### IN THE TITLE PAGES:

In Item [56] References Cited, in U.S. PATENT DOCUMENTS: please add the following reference: --6,001,846 A 12/1999 Edwards et al. 514/285--in 6,566,358 please replace "Zhi et al." with --Zhang et a1.--in 6,566,372 please replace "West et al." with --Zhi et al.--

In Item [56] References Cited, in OTHER PUBLICATIONS: in Hamann et al., please replace "dihyrdo" with --dihydro--

At column 8, Table A, row R<sup>1</sup>, please replace "C<sub>1</sub>-C haloalkyl" with --C<sub>1</sub>-C<sub>4</sub> haloalkyl-at column 9, Table A, row R<sup>9</sup>, please replace "CONR<sup>H</sup>R<sup>12</sup>" with --CONR<sup>11</sup>R<sup>12</sup>--at column 11, Table A, below row R<sup>16</sup>, please replace "R<sup>15</sup>" with --R<sup>16</sup>--

Please replace Claims 12, 13, 14, and 15 with the following Claims:

Col. 40

12. A compound of the formula:

**(I)** 

wherein:

R<sup>1</sup> is selected from the group of hydrogen, C<sub>1</sub>–C<sub>4</sub> alkyl, C<sub>1</sub>–C<sub>4</sub> haloalkyl, C<sub>1</sub>–C<sub>4</sub> heteroalkyl, COR<sup>11</sup>, CO<sub>2</sub>R<sup>11</sup>, SO<sub>2</sub>R<sup>11</sup>, and CONR<sup>11</sup>R<sup>12</sup>;

 $R^2$  and  $R^3$  each independently is selected from the group of hydrogen,  $C_1$ – $C_6$  alkyl, and  $C_1$ – $C_6$  haloalkyl; or

R<sup>2</sup> and R<sup>3</sup> taken together form a cycloalkyl ring of from three to twelve carbons;

 $R^4$  through  $R^7$  each independently is selected from the group of hydrogen, F, C1, Br, CN,  $OR^{11}$ ,  $C_1$ – $C_4$  alkyl,  $C_1$ – $C_4$  haloalkyl, and  $C_1$ – $C_4$  heteroalkyl; or

R<sup>5</sup> and R<sup>7</sup> taken together form a bond; or

R<sup>6</sup> and R<sup>7</sup> taken together are selected from the group of methylidene, mono-substituted methylidene, di-substituted methylidene and carbonyl;

#### **CERTIFICATE OF CORRECTION**

PATENT NO.

: 7,071,205 B2

Page 2 of 10

APPLICATION NO.: 10/684229

**DATED** INVENTOR(S) : July 4, 2006 : Lin Zhi et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

 $R^8$  through  $R^{10}$  each independently is selected from the group of hydrogen, F, Cl, Br, I, NO2, CN,  $OR^{11},\,NR^{11}R^{12},\,SR^{11},\,COR^{11},\,CO_2R^{11},\,CONR^{11}R^{12},\,C_1\!-\!C_8$  alkyl,  $C_1\!-\!C_8$ heteroalkyl, C<sub>1</sub>–C<sub>8</sub> haloalkyl, allyl, C<sub>2</sub>–C<sub>8</sub> alkenyl and C<sub>2</sub>–C<sub>8</sub> alkynyl;

R<sup>11</sup> and R<sup>12</sup> each is independently selected from the group of hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl,  $C_1$ – $C_4$  heteroalkyl, and  $C_1$ – $C_4$  haloalkyl;

R<sup>13</sup> is hydrogen;

 $R^{14}$  and  $R^{16}$  taken together form a bond or "-O-" bridge;  $R^{15}$ ,  $R^{17}$ ,  $R^{18}$ ,  $R^{19}$ ,  $R^{20}$  each independently is selected from the group of hydrogen, F, C1,  $C_1$ – $C_4$  alkyl, and  $C_1$ – $C_4$  haloalkyl;

R<sup>21</sup> is hydrogen; and

n is 0, 1, 2, or 3;

or a pharmaceutically acceptable salt thereof.

Col. 41

13. A compound of the formula:

**(I)** 

## CERTIFICATE OF CORRECTION

PATENT NO.

: 7,071,205 B2

Page 3 of 10

APPLICATION NO.: 10/684229 DATED

: July 4, 2006

INVENTOR(S)

: Lin Zhi et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

#### wherein:

R<sup>1</sup> is selected from the group of hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> heteroalkyl, COR<sup>11</sup>, CO<sub>2</sub>R<sup>11</sup>, SO<sub>2</sub>R<sup>11</sup>, and CONR<sup>11</sup>R<sup>12</sup>;

R<sup>2</sup> and R<sup>3</sup> each independently is selected from the group of hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, and C<sub>1</sub>-C<sub>6</sub> haloalkyl; or

R<sup>2</sup> and R<sup>3</sup> taken together form a cycloalkyl ring of from three to twelve carbons;

R<sup>4</sup> through R<sup>7</sup> each independently is selected from the group of hydrogen, F, Cl, Br, CN,  $OR^{11}$ ,  $C_1$ – $C_4$  alkyl,  $C_1$ – $C_4$  haloalkyl, and  $C_1$ – $C_4$  heteroalkyl; or

R<sup>5</sup> and R<sup>7</sup> taken together form a bond; or

R<sup>6</sup> and R<sup>7</sup> taken together are selected from the group of methylidene, mono-substituted methylidene, di-substituted methylidene and carbonyl;

R<sup>8</sup> through R<sup>10</sup> each independently is selected from the group of hydrogen, F. Cl. Br. I. NO<sub>2</sub>, CN, OR<sup>11</sup>, NR<sup>11</sup>R<sup>12</sup>, SR<sup>11</sup>, COR<sup>11</sup>, CO<sub>2</sub>R<sup>11</sup>, CONR<sup>11</sup>R<sup>12</sup>, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> heteroalkyl, C<sub>1</sub>–C<sub>8</sub> haloalkyl, allyl, C<sub>2</sub>–C<sub>8</sub> alkenyl and C<sub>2</sub>–C<sub>8</sub> alkynyl;

R<sup>11</sup> and R<sup>12</sup> each is independently selected from the group of hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl,  $C_1$ –  $C_4$  heteroalkyl, and  $C_1$ – $C_4$  haloalkyl;

R<sup>13</sup> is hydrogen;

R<sup>14</sup>, R<sup>15</sup>, R<sup>18</sup>, R<sup>19</sup>, R<sup>20</sup> each independently is selected from the group of hydrogen, F, Cl,  $C_1$ – $C_4$  alkyl, and  $C_1$ – $C_4$  haloalkyl;

R<sup>16</sup> and R<sup>17</sup> taken together are selected from the group of methylidene, mono-substituted methylidene, and di-substituted methylidene;

R<sup>21</sup> is hydrogen; or

R<sup>21</sup> and R<sup>20</sup> taken together form a bond:

n is 0, 1, 2, or 3;

or a pharmaceutically acceptable salt thereof.

### **CERTIFICATE OF CORRECTION**

PATENT NO. : 7,071,205 B2 APPLICATION NO. : 10/684229

DATED : July 4, 2006
INVENTOR(S) : Lin Zhi et al.

Page 4 of 10

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Col. 42

14. A compound of the formula:

**(I)** 

wherein:

 $R^1$  is selected from the group of hydrogen,  $C_1$ – $C_4$  alkyl,  $C_1$ – $C_4$  haloalkyl,  $C_1$ – $C_4$  heteroalkyl,  $CO_2R^{11}$ ,  $SO_2R^{11}$ , and  $CONR^{11}R^{12}$ ;

 $R^2$  and  $R^3$  each independently is selected from the group of hydrogen,  $C_1$ – $C_6$  alkyl, and  $C_1$ – $C_6$  haloalkyl; or

R<sup>2</sup> and R<sup>3</sup> taken together form a cycloalkyl ring of from three to twelve carbons;

R<sup>4</sup> through R<sup>7</sup> each independently is selected from the group of hydrogen, F, Cl, Br, CN, OR<sup>11</sup>, C<sub>1</sub>–C<sub>4</sub> alkyl, C<sub>1</sub>–C<sub>4</sub> haloalkyl, and C<sub>1</sub>–C<sub>4</sub> heteroalkyl; or

R<sup>5</sup> and R<sup>7</sup> taken together form a bond; or

R<sup>6</sup> and R<sup>7</sup> taken together are selected from the group of methylidene, mono-substituted methylidene, di-substituted methylidene and carbonyl;

 $R^8$  through  $R^{10}$  each independently is selected from the group of hydrogen, F, Cl, Br, I, NO<sub>2</sub>, CN, OR<sup>11</sup>, NR<sup>11</sup>R<sup>12</sup>, SR<sup>11</sup>, COR<sup>11</sup>, CO<sub>2</sub>R<sup>11</sup>, CONR<sup>11</sup>R<sup>12</sup>, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> heteroalkyl, C<sub>1</sub>-C<sub>8</sub> haloalkyl, allyl, C<sub>2</sub>-C<sub>8</sub> alkenyl and C<sub>2</sub>-C<sub>8</sub> alkynyl;

### CERTIFICATE OF CORRECTION

PATENT NO. : 7,071205 B2

APPLICATION NO.: 10/684229 DATED: July 4, 2006

DATED : July 4, 2006 INVENTOR(S) : Lin Zhi et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

 $R^{11}$  and  $R^{12}$  each is independently selected from the group of hydrogen,  $C_1$ – $C_4$  alkyl,  $C_1$ – $C_4$  heteroalkyl, and  $C_1$ – $C_4$  haloalkyl;

Page 5 of 10

R<sup>13</sup> is hydrogen;

 $R^{14}$ ,  $R^{15}$ ,  $R^{17}$ ,  $R^{20}$  each independently is selected from the group of hydrogen, F, Cl, C<sub>1</sub>–C<sub>4</sub> alkyl, and C<sub>1</sub>–C<sub>4</sub> haloalkyl;

R<sup>16</sup> and R<sup>18</sup> taken together form a bond when n is 1;

R<sup>16</sup> and R<sup>19</sup> taken together form a bond when n is 0;

R<sup>21</sup> is hydrogen; and

n is 0, 1, 2, or 3;

or a pharmaceutically acceptable salt thereof.

Col. 42-45

15. A Compound selected from the group of:

(±)-(51,1'l)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 24);

(±)-(51,1'u)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 25);

(+)-(51,1'1)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 27);

(-)-(51,1'l)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 28);

(±)-(51,1'1)-5-(3-methyl-2-cyclohexenyl)-9-hydroxy-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 29);

# UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : 7,071,205 B2 Page 6 of 10

APPLICATION NO.: 10/684229 DATED: July 4, 2006 INVENTOR(S): Lin Zhi et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

(±)-(51,1'u)-5-(3-methyl-2-cyclohexenyl)-9-hydroxy-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 30):

- (+)-(51,1'1)-5-(3-methyl-2-cyclohexenyl)-9-hydroxy-1,2-dihydro-2,2,4-trimethyl-5H-cbromeno[3,4-fiquinoline (compound 32);
- (-)-(51,1'1)-5-(3-methyl-2-cyclohexenyl)-9-hydroxy-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-fJquinoline (compound 33);
- (±)-(51,1'1)-5-3-methy1-2-cyclohexeny1)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 34);
- (±)-(51,1'u)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 35);
- (+)-(51,1'1)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 37);
- (-)-(51,1'1)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 38);
- (±)-(51,1'1)-5-(3-methyl-2-cyclohexenyl)-9-methoxy-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 39);
- (±)-(51,1'1)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2-dimethyl-5H-chromeno[3,4-f]quinoline (compound 41);
- (±)-(51,1'u)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2-dimethyl-5H-chromeno[3,4-f]quinoline (compound 42);
- (±)-(51,1'1)-5-(3-methy1-2-cyclopenteny1)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 44);
- (±)-(51,1'u)-5-(3-methyl-2-cyclopentenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethy-5H-chromeno[3,4-f]quinoline (compound 45);

#### CERTIFICATE OF CORRECTION

PATENT NO. : 7,071,205 B2 APPLICATION NO. : 10/684229

DATED : July 4, 2006
INVENTOR(S) : Lin Zhi et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

(±)-(51,1'1)-5-(3,5,5-trimethyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 47);

Page 7 of 10

- (±)-(51,1'u)-5-(3,5,5-trimethyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 48);
- (±)-(51,1'1)-5-(3-methyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 50);
- (±)-(51,1'u)-5-(3-methyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 51):
- (±)-5-(3-methyl-3-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 52);
- (±)-5-(2-cyclopenta-1,3-dienyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 53);
- (±)-(51,1'1)-5-(3-ethy1-2-cyclohexeny1)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 55);
- (±)-(51,1'u)-5-(3-ethyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 56);
- (±)-(51,1'1)-5-(3-methyl-2-cyclohexenyl)-7-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 58);
- (±)-(51,1'u)-5-(3-methy1-2-cyclohexeny1)-7-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 59);
- (±)-(51,1'1)-5-(3-ethyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 61);
- (±)-(51,1'1)-5-(3-ethylidenecyclohexyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 62);

# **CERTIFICATE OF CORRECTION**

PATENT NO. : 7,071,205 B2 Page 8 of 10

APPLICATION NO.: 10/684229
DATED: July 4, 2006
INVENTOR(S): Lin Zhi et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

(±)-(51,1'1)-5-(3-methyl-3-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 63):

- (±)-(51,1'1)-5-(3-methyl-2-cyclobexenyl)-9-fluoro-1,2-dihydro-8-methoxy-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 64);
- (±)-(51,1'u)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-8-methoxy-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 65);
- (±)-(51,1'1)-5-(2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 67);
- (±)-(51,1'u)-5-(2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 68);
- (±)-5-(1-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 69);
- (±)-(51,1'1)-5-(2,3-dimethyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 71);
- (+)-(51,1'1)-5-(2,3-dimethyl-2-eyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 73);
- (-)-(51,1'1)-5-(2,3-dimethyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 74);
- (±)-(51,1'1)-5-(2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 75);
- (±)-(51,1'u)-5-(2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 76);
- (±)-(51,1'1)-5-(2-cyclohexenyl)-7,9-difluoro-1,2,3,4-tetrahydro-2,2-dimethyl-4-methylidene-5H-chromeno[3,4-f]quinoline (compound 77);

### **CERTIFICATE OF CORRECTION**

PATENT NO. : 7,071,205 B2 Page 9 of 10

APPLICATION NO.: 10/684229
DATED: July 4, 2006
INVENTOR(S): Lin Zhi et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

(±)-(51,1'1)-5-(2-methylidenecyclohexyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 79);

- (±)-(51,1'u)-5-(2-methylidenecyclohexyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 80);
- (±)-(51,1'1)-5-(2-oxocyclohexyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 81);
- (±)-(51,1'u)-5-(2-oxocyclohexyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 82);
- (±)-(51,1'1)-5-(3-methyl-2-cyclohexenyl)-9-methoxy-1,2-dihydro-1,2,2,4-tetramethyl-5H-chromeno[3,4-f]quinoline (compound 83);
- (±)-5-(2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]-quinoline (compound 84);
- (±)-(51,1'1)-5-(2,3-dimethyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 85);
- (±)-5-(3-methyl idene-cyclohexyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 87);
- (±)-(51,1'u)-5-(3-ethylidenecyclohexyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 88);
- (±)-(51,1'1)-5-(2-cycl oheptenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 89);
- (±)-(51,1'1)-5-(2-cyclooctenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 91);
- (±)-(51,1'u)-5-(2-cyclooctenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 92);

# UNITED STATES PATENT AND TRADEMARK OFFICE **CERTIFICATE OF CORRECTION**

PATENT NO. : 7,071,205 B2

APPLICATION NO.: 10/684229 DATED : July 4, 2006 INVENTOR(S) : Lin Zhi et al.

> It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

- (±)-(51,1'1)-5-(2,3-epoxy-3-methylcyclohexyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 94);
- (±)-(51,1'1)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2,3,4-tetrahydro-2,2-dimethyl-4methylene-5H-chromeno[3,4-f]quinolin-3-ol (Compound 95);
- (±)-(51,1'1)-5-(2,3-epoxy-2,3-dimethylcyclopentyl)-7,9-difluoro-1,2-dihydro-2,2,4trimethyl-5H-chromeno[3,4-f]quinoline (Compound 96);
- $(\pm)$ -(51,1'u)-5-(2,3-epoxy-3-methylcyclohexyl)-7,9-difluoro-1,2-dihydro-2,2,4trimethy1-5H-chromeno[3,4-f]quinoline (Compound 97); and
- (±)-(51,1'1)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2,3,4-tetrahydro-2,2-dimethyl-5H-chromeno[3,4-f]quinolin-4-one (Compound 98).

This certificate supersedes Certificate of Correction issued November 28, 2006.

Signed and Sealed this

Page 10 of 10

Third Day of April, 2007

JON W. DUDAS Director of the United States Patent and Trademark Office